Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

@article{ToftNielsen1999ContinuousSI,
  title={Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.},
  author={M B Toft-Nielsen and Sten Madsbad and Jens Juul Holst},
  journal={Diabetes care},
  year={1999},
  volume={22 7},
  pages={1137-43}
}
OBJECTIVE The gut hormone glucagon-like peptide 1 (GLP-1) has insulinotropic and anorectic effects during intravenous infusion and has been proposed as a new treatment for type 2 diabetes and obesity. The effect of a single subcutaneous injection is brief because of rapid degradation. We therefore sought to evaluate the effect of infusion of GLP-1 for 48 h in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS We infused GLP-1 (2.4 pmol.kg-1.min-1) or saline subcutaneously for 48 h in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 129 extracted citations

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

American journal of physiology. Endocrinology and metabolism • 2001
View 4 Excerpts
Highly Influenced

Protein-induced satiation and the calcium-sensing receptor

Diabetes, metabolic syndrome and obesity : targets and therapy • 2018

Similar Papers

Loading similar papers…